Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating new capacity and flexibility for GSK to invest in growth and innovation for patients and shareholders.
Tag Archive for: GlaxoSmithKline
GSK reported Wednesday its checkpoint inhibitor Jemperli yielded positive data in non-small cell lung cancer, moving the monoclonal antibody potentially closer to the market in this indication.
Shares of Spero Therapeutics soared in premarket trading following GlaxoSmithKline’s announcement that it will license the company’s late-stage antibiotic asset, tebipenem HBr, a potential treatment for complicated urinary tract infections.
Haleon believes it is not liable for any claims that may arise from U.S. litigation over the heartburn drug Zantac, the London-listed company’s CEO Brian McNamara told Reuters on Tuesday.
Encouraging new data on a malaria vaccine from Oxford University bodes well for global effort to combat the mosquito-borne disease that kills a child every minute, its makers said on Wednesday.
South Korea-based Genuv Inc. announced the publication of a preclinical study showing that Mekinist (trametinib), approved by the FDA for melanoma, has a neuroprotective effect in Alzheimer’s disease.
Clinical-stage biopharma company Mersana Therapeutics unveiled a global collaboration with GlaxoSmithKline Monday that gives the industry behemoth the exclusive option to co-develop and commercialize Mersana’s antibody-drug conjugate (ADC) XMT-2056.
The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the 2022 Prix Galien USA Award nominees for “Best Biotechnology Product,” “Best Pharmaceutical Agent,” and “Best Medical Technology.” Winners will be announced during the Prix Galien USA Awards Ceremony on October 27, 2022, at the American Museum of Natural History in New York City.
When GlaxoSmithKline’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.
CureVac has filed a patent lawsuit in Germany against BioNTech over its use of mRNA technology, marking one of the first known cases of a company going to court amid the fierce competition to develop a vaccine against the coronavirus.
